Potential roles of oxidative distress on neurodegeneration in Parkinson's disease with neuropsychiatric symptoms
暂无分享,去创建一个
Wei-jiao Zhang | Ya-nan Zhang | Wei Zhang | Peng Guo | Teng-hong Lian | Dan-ning Li | Huiyun Guan | Mingyi He | Weijiao Zhang | Wen-jing Zhang | Xiao-min Wang | Jing-hui Li | D. Luo
[1] L. Zuo,et al. Clinical Characteristics, Iron Metabolism and Neuroinflammation: New Insight into Excessive Daytime Sleepiness in Parkinson’s Disease , 2021, Neuropsychiatric disease and treatment.
[2] T. Révész,et al. Neuropathological and Biomarker Findings in Parkinson’s Disease and Alzheimer’s Disease: From Protein Aggregates to Synaptic Dysfunction , 2020, Journal of Parkinson's disease.
[3] G. Grant,et al. Investigating the Convergent Mechanisms between Major Depressive Disorder and Parkinson’s Disease , 2020, Complex Psychiatry.
[4] Xiao-Min Wang,et al. Parkinson’s Disease With Depression: The Correlations Between Neuroinflammatory Factors and Neurotransmitters in Cerebrospinal Fluid , 2020, Frontiers in Aging Neuroscience.
[5] A. Cuadrado,et al. Inflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications , 2020, Cells.
[6] Qianjun He,et al. Nitric oxide detection methods in vitro and in vivo , 2019, Medical gas research.
[7] D. D. Di Monte,et al. Oxidative stress in vagal neurons promotes parkinsonian pathology and intercellular α-synuclein transfer. , 2019, The Journal of clinical investigation.
[8] A. Schrag,et al. Neuropsychiatric aspects of Parkinson’s disease , 2019, Journal of Neural Transmission.
[9] L. Zuo,et al. Tremor-Dominant in Parkinson Disease: The Relevance to Iron Metabolism and Inflammation , 2019, Front. Neurosci..
[10] Laura Avanzino,et al. Relationships between gait and emotion in Parkinson's disease: A narrative review. , 2018, Gait & posture.
[11] K. Hassanzadeh,et al. Oxidative stress and neuroinflammation in the story of Parkinson’s disease: Could targeting these pathways write a good ending? , 2018, Journal of cellular physiology.
[12] D. Ffytche,et al. Assessment and Management of Neuropsychiatric Symptoms in Parkinson’s Disease , 2018, CNS Drugs.
[13] K. Hassanzadeh,et al. Thymoquinone exerts neuroprotective effect in animal model of Parkinson's disease. , 2017, Toxicology letters.
[14] V. Lee,et al. Synthetic alpha-synuclein fibrils cause mitochondrial impairment and selective dopamine neurodegeneration in part via iNOS-mediated nitric oxide production , 2017, Cellular and Molecular Life Sciences.
[15] J. Schott,et al. Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study , 2017, The Lancet Neurology.
[16] Manoj Kumar,et al. INGE GRUNDKE-IQBAL AWARD FOR ALZHEIMER’S RESEARCH: NEUROTOXIC REACTIVE ASTROCYTES ARE INDUCED BY ACTIVATED MICROGLIA , 2019, Alzheimer's & Dementia.
[17] M. Kuijf,et al. Prevalence of anxiety in Parkinson's disease: A systematic review and meta‐analysis , 2016, Movement disorders : official journal of the Movement Disorder Society.
[18] P. Krack,et al. Emotional manifestations of PD: Neurobiological basis , 2016, Movement disorders : official journal of the Movement Disorder Society.
[19] Xiaomin Wang,et al. Excessive Iron and α-Synuclein Oligomer in Brain are Relevant to Pure Apathy in Parkinson Disease , 2016, Journal of geriatric psychiatry and neurology.
[20] Fang Wang,et al. Parkinson's Disease with Fatigue: Clinical Characteristics and Potential Mechanisms Relevant to α-Synuclein Oligomer , 2016, Journal of clinical neurology.
[21] G. Deuschl,et al. MDS clinical diagnostic criteria for Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.
[22] N. Kandiah,et al. Influence of depression in mild Parkinson's disease on longitudinal motor and cognitive function. , 2015, Parkinsonism & related disorders.
[23] Fang Wang,et al. Parkinson disease with REM sleep behavior disorder , 2015, Neurology.
[24] H. Berendse,et al. Depressive symptoms in Parkinson's disease are related to decreased hippocampus and amygdala volume , 2015, Movement disorders : official journal of the Movement Disorder Society.
[25] L. Defebvre,et al. Apathy in untreated early‐stage Parkinson disease: Relationship with other non‐motor symptoms , 2014, Movement disorders : official journal of the Movement Disorder Society.
[26] H. Shill,et al. Plaques and tangles as well as Lewy-type alpha synucleinopathy are associated with formed visual hallucinations. , 2014, Parkinsonism & related disorders.
[27] M. Hornberger,et al. Neuropsychiatric symptoms in Parkinson's disease: fronto-striatal atrophy contributions. , 2014, Parkinsonism & related disorders.
[28] B. Kalyanaraman,et al. Mitochondria-targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes. , 2014, Biochimica et biophysica acta.
[29] L. Defebvre,et al. Apathy in Parkinson's disease is associated with nucleus accumbens atrophy: A magnetic resonance imaging shape analysis , 2014, Movement disorders : official journal of the Movement Disorder Society.
[30] F. Wang,et al. Potential biomarkers relating pathological proteins, neuroinflammatory factors and free radicals in PD patients with cognitive impairment: a cross-sectional study , 2014, BMC Neurology.
[31] N. Chandel,et al. ROS Function in Redox Signaling and Oxidative Stress , 2014, Current Biology.
[32] Stephanie D. Wilson,et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. , 2014, JAMA neurology.
[33] Lei Liu,et al. Oxidative stress induces gastric submucosal arteriolar dysfunction in the elderly. , 2013, World journal of gastroenterology.
[34] Xiao-Min Wang,et al. Sleep Disorders in Parkinson’s Disease: Clinical Features, Iron Metabolism and Related Mechanism , 2013, PloS one.
[35] S. Gentleman,et al. Disturbed sleep in Parkinson's disease: anatomical and pathological correlates , 2013, Neuropathology and applied neurobiology.
[36] Sara Hall,et al. Cerebrospinal fluid inflammatory markers in Parkinson’s disease – Associations with depression, fatigue, and cognitive impairment , 2013, Brain, Behavior, and Immunity.
[37] R. de la Fuente-Fernández. Imaging of Dopamine in PD and Implications for Motor and Neuropsychiatric Manifestations of PD , 2013, Front. Neurol..
[38] D. Surmeier,et al. Calcium Entry and α-Synuclein Inclusions Elevate Dendritic Mitochondrial Oxidant Stress in Dopaminergic Neurons , 2013, The Journal of Neuroscience.
[39] R. Camicioli,et al. Intact limbic-prefrontal connections and reduced amygdala volumes in Parkinson's disease with mild depressive symptoms. , 2012, Parkinsonism & related disorders.
[40] M. Martínez-Banaclocha. N-acetyl-cysteine in the treatment of Parkinson's disease. What are we waiting for? , 2012, Medical hypotheses.
[41] Kathleen R. Bogart. Is apathy a valid and meaningful symptom or syndrome in Parkinson's disease? A critical review. , 2011, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.
[42] Yi Zhu,et al. Leonurine Protects Middle Cerebral Artery Occluded Rats Through Antioxidant Effect and Regulation of Mitochondrial Function , 2010, Stroke.
[43] Wim E J Weber,et al. Neuroanatomical correlates of apathy in Parkinson's disease: A magnetic resonance imaging study using voxel‐based morphometry , 2010, Movement disorders : official journal of the Movement Disorder Society.
[44] M Filippi,et al. Regional patterns of brain tissue loss associated with depression in Parkinson disease , 2010, Neurology.
[45] L. Tremblay,et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. , 2010, Brain : a journal of neurology.
[46] Guido Alves,et al. Epidemiology of psychosis in Parkinson's disease , 2010, Journal of the Neurological Sciences.
[47] João Ricardo Sato,et al. Depression in Parkinson's disease: Convergence from voxel-based morphometry and functional magnetic resonance imaging in the limbic thalamus , 2009, NeuroImage.
[48] C. Ríos,et al. Free Copper, Ferroxidase and SOD1 Activities, Lipid Peroxidation and NOx Content in the CSF. A Different Marker Profile in Four Neurodegenerative Diseases , 2008, Neurochemical Research.
[49] Z. Illés,et al. Morphometric changes of gray matter in Parkinson's disease with depression: A voxel‐based morphometry study , 2008, Movement disorders : official journal of the Movement Disorder Society.
[50] M. Barrachina,et al. Abnormal levels of prohibitin and ATP synthase in the substantia nigra and frontal cortex in Parkinson's disease , 2007, Neuroscience Letters.
[51] J. Snaedal,et al. Ceruloplasmin and superoxide dismutase (SOD1) in Parkinson's disease: A follow-up study , 2006, Journal of the Neurological Sciences.
[52] C. Marsden,et al. A Selective Increase in Particulate Superoxide Dismutase Activity in Parkinsonian Substantia Nigra , 1989, Journal of neurochemistry.
[53] R. Marttila,et al. Oxygen toxicity protecting enzymes in Parkinson's disease Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus , 1988, Journal of the Neurological Sciences.
[54] R. Hider,et al. Colorimetric detection of the hydroxyl radical: comparison of the hydroxyl-radical-generating ability of various iron complexes. , 1988, Analytical biochemistry.
[55] D. Aarsland,et al. Neuropsychiatric Symptoms in Parkinson's Disease. , 2015, Journal of Parkinson's disease.